CODX vs. ICAD, PYPD, APYX, KRMD, SRTS, BLUA, BWAY, ALUR, STIM, and PDEX
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include iCAD (ICAD), PolyPid (PYPD), Apyx Medical (APYX), KORU Medical Systems (KRMD), Sensus Healthcare (SRTS), BlueRiver Acquisition (BLUA), BrainsWay (BWAY), Allurion Technologies (ALUR), Neuronetics (STIM), and Pro-Dex (PDEX).
Co-Diagnostics (NASDAQ:CODX) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.
In the previous week, Co-Diagnostics and Co-Diagnostics both had 3 articles in the media. Co-Diagnostics' average media sentiment score of 1.19 beat iCAD's score of 1.01 indicating that Co-Diagnostics is being referred to more favorably in the media.
Co-Diagnostics received 45 more outperform votes than iCAD when rated by MarketBeat users. Likewise, 63.34% of users gave Co-Diagnostics an outperform vote while only 62.81% of users gave iCAD an outperform vote.
iCAD has a net margin of -15.20% compared to Co-Diagnostics' net margin of -582.36%. iCAD's return on equity of -14.00% beat Co-Diagnostics' return on equity.
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 24.6% of iCAD shares are held by institutional investors. 2.4% of Co-Diagnostics shares are held by insiders. Comparatively, 12.0% of iCAD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
iCAD has higher revenue and earnings than Co-Diagnostics. iCAD is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Co-Diagnostics has a beta of -0.65, indicating that its share price is 165% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.
Co-Diagnostics presently has a consensus price target of $2.00, indicating a potential upside of 90.48%. iCAD has a consensus price target of $5.00, indicating a potential upside of 244.83%. Given iCAD's higher probable upside, analysts clearly believe iCAD is more favorable than Co-Diagnostics.
Summary
iCAD beats Co-Diagnostics on 10 of the 15 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
